Drugs / IPAFRICEPT
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02092363 | Jan 2014 → Oct 2017 | ovarian cancer | OncoMed Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02069145 | Jan 2014 → May 2017 | hepatocellular carcinoma | OncoMed Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02050178 | Nov 2013 → Jun 2017 | malignant pancreatic neoplasm | OncoMed Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01608867 | Jun 2012 → Aug 2016 | cancer | OncoMed Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IPAFRICEPT | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301577 ↗ |
| Known as | OMP-54F28 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02092363 ↗ |
| Action | Inhibit | “Frizzled-8 antagonist” CHEMBL3301577 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL3301577 ↗ |
| Route | Intravenous | “10 mg/kg administered IV once every 3 weeks” NCT01608867 ↗ |
| Target | FZD8 | “Frizzled-8 antagonist” CHEMBL3301577 ↗ |